# Diabetes Research Hub — Iteration Run 2026-07-12 (Sun)

## State loaded
- 285 papers tracked: 272 VETTED / 13 FLAGGED / 0 unvetted
- 57 research paths (56 in validated_paths); 15 gaps
- Work queue: 31 items (priority-ordered)
- Run #89 in history

## Work performed
1. **Credibility sweep (every run) — CLEAN.** 0 fabricated PMIDs (>42M) in scripts; 0 "zero SAEs/zero rejection"; only "curative" matches are the detector regex inside verify_before_deploy.py.
2. **Path validation — Treg_expansion → T1D (stalest distinct PARTIALLY, last touch 2026-06-26).** Reaffirmed **PARTIALLY_VALIDATED**. Web sweep found no efficacy-powered Treg RCT readout since June. T-Rex phase 2 (single-dose polyclonal expTreg, PMID 38718135) remains the pivotal negative — safe but no C-peptide preservation in new-onset pediatric T1D; Treg *quality* implicated. ld-IL-2 shows robust human target engagement (interval dosing expands thymic FOXP3+HELIOS+ Tregs) but no consistent beta-cell preservation — paradoxical dissociation persists. New activity is early-phase only (CD6-CAR Treg T1D trial recruiting, no efficacy data). No tier change.
3. **Pipeline rebuild — run_quality_improvements.py: all 41 stages [OK].** PMID verification 262/262 verified (0 not found, 0 API errors).

## Not due this run
- Weekly PubMed sweep skipped (not Monday).
- Most search_pubmed watches (Tegoprubart, verapamil Ver-A-T1D, PROTECT, DAPAN-DIA, SAB-142, BANDIT) scheduled 2026-08-02 / 2026-09-02.
- Gap audits: nearest due Gap #5 ~07-18, Gap #13 ~07-19, Gap #11 ~07-20 — not yet due.

## Blocker (persistent)
- **git push BLOCKED** — requires user GitHub auth. Local commits accumulate; HEAD remains ahead of origin. Manual_cleanup_required item #0 stays P1.

## Next run pointers
- Validate next-stalest distinct PARTIALLY path: metformin → cardiovascular (2026-06-25) or TXNIP_NLRP3_beta_cell_DKD (2026-06-26).
- Gap #5 audit becomes due ~07-18.
